-
Group
BackGroupView
-
Who we are
BackWho we areView
- Profile
- Key figures
-
Governance
BackGovernanceView
-
Governance
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Our history
-
Who we are
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
What we do
BackWhat we doView
- At a glance
- Large Industries
- Industrial Merchant
- Healthcare
- Electronics
- Engineering & Construction
- Global Markets & Technologies
-
What we do
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Our strategy
BackOur strategyView
-
Our strategy
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Innovation
BackInnovationView
-
Research & Development
BackResearch & DevelopmentView
-
Research & Development
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Digital transformation
-
Global markets & Technologies
BackGlobal markets & TechnologiesView
-
Global markets & Technologies
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Air Liquide Venture Capital
-
Innovation
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Research & Development
-
Sustainable development
BackSustainable developmentView
- Safety
-
Ethics
BackEthicsView
-
Ethics
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Human rights
- Climate objectives
- Environmental data
- Vigilance plan
- Extra-financial ratings
-
Stakeholders
BackStakeholdersView
-
Stakeholders
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Sustainable development
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Where we operate
- Group publications
-
Group
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Who we are
-
Businesses
BackBusinessesView
-
Industry
BackIndustryView
-
Industry
-
Healthcare
BackHealthcareView
- Presentation
-
Our expertise
-
Our R&D
- Diseases
-
Public health challenges
BackPublic health challengesView
- Aging population
- Rise in chronic diseases
- Urbanization and lifestyle changes
- Reinventing the hospital
-
Public health challenges
-
Healthcare
-
Electronics
-
Engineering & Construction
BackEngineering & ConstructionView
-
Engineering & Construction
-
Science & New energies
BackScience & New energiesView
-
Science & New energies
-
Businesses
-
Industry
-
Magazine
BackMagazineView
- Industry of the future
- Healthcare
- Energy transition
- Customer experience
- Digitization
- Open innovation
- Science
-
Magazine
- Customers
-
Shareholders
BackShareholdersView
- Stock & Share: shareholders' mag
- Become a shareholder
-
Follow the Air Liquide share
BackFollow the Air Liquide shareView
-
Follow the Air Liquide share
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
-
Factsheets
BackFactsheetsView
- Understanding the stock market
- Stock orders
- Shareholding options
- Registering shares
- Loyalty bonus
- Personal online Account
- Capital gains
- Free share attribution
- Dividend
- Taxation
- Passing on shares
-
Factsheets
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
- Shareholders' Communication Committee
- Annual General Meeting
- Agenda
-
Media library
BackMedia libraryView
-
Media library
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
- Contact us
-
Shareholders
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
-
Investors
BackInvestorsView
- Agenda
- Documents & Presentations
- Vara consensus
-
Investing in Air Liquide
BackInvesting in Air LiquideView
-
Investing in Air Liquide
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
-
Credit investor
BackCredit investorView
-
Credit investor
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
-
Governance
BackGovernanceView
- Corporate officers remuneration and regulated commitments
- Board committees
- Capital and articles of association, Internal Regulations, disclosure of share buy-back transactions
-
Governance
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
- Regulated information
- Contact us
-
Investors
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
-
Media
-
Careers
BackCareersView
- Job offers
- I choose Air Liquide
-
Careers at Air Liquide
BackCareers at Air LiquideView
-
Careers at Air Liquide
- Find our job offers
- Spontaneous application
-
You at Air Liquide
BackYou at Air LiquideView
-
You at Air Liquide
- Find our job offers
- Spontaneous application
- Students
-
Graduates
BackGraduatesView
-
Graduates
- Find our job offers
- Spontaneous application
Healthcare: Air Liquide strengthens its position in home care for patients with diabetes and participates in the French artificial pancreas project
By signing a partnership with CERITD, the French Center for Studies and Research for the Intensification of Diabetes Treatment, Air Liquide is strengthening its position in home healthcare for patients with diabetes. Air Liquide also acquired an equity stake in “Diabeloop”, the French start-up that is developing an electronic artificial pancreas.
With this new collaboration, Air Liquide continues the approach initiated by CERITD based on cooperation between hospital teams and homecare nurses. At the request of physicians, nurses will be able to help provide even more personalized follow-up for patients with diabetes treated at home, such as adjusting the treatment in accordance with a strict protocol.
In addition, to increase its level of expertise in the field of diabetes and support innovation, Air Liquide has acquired an equity stake via ALIAD, the Group’s venture capital investment arm, in the French start-up Diabeloop, which is developing its own artificial pancreas. Founded by CERITD’s diabetes specialists, in partnership with the CEA Leti,1 Diabeloop is designing an electronic artificial pancreas composed of an insulin pump in the form of a patch and a glucose sensor both connected. Driven by an algorithm, this system will enable to automate the delivery of insulin and thus reproduce the functions of the defective pancreas.
In practice, using the data collected by the continuous glucose sensor, the algorithm determines the right dose of insulin, which is then delivered in real time via the insulin pump in order to improve patient glucose regulation.
This technology will help improve the daily life of patients with type 1 diabetes by partially automating the management of this disease. The investment made by Air Liquide in Diabeloop confirms the Group’s commitment to digital technologies and healthcare, in the aim of helping patients achieve a better quality of life and care.
François Jackow, member of the Air Liquide group’s Executive Committee, supervising the Healthcare activities, said: "The partnership with CERITD, a leading research center for diabetes treatment, and investments in innovative projects such as Diabeloop's electronic artificial pancreas, are in line with the development strategy of Air Liquide's Home Healthcare activity. By relying on innovation ecosystems, Air Liquide is contributing to advances in home care for patients with chronic illnesses."
1 Electronics laboratory for information technology of the CEA (The French Alternative Energies and Atomic Energy Commission)
Supplies medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients. In 2016, it served over 15,000 hospitals and clinics and more than 1.4 million patients at home throughout the world. The Group’s Healthcare business reached €3,111 million in revenues in 2016, with the support of its 15,000 employees.
Air Liquide, European leader in home healthcare, provides home healthcare services in compliance with medical prescription for patients suffering from chronic diseases such as COPD (Chronic Obstructive Pulmonary Disease), sleep apnea and diabetes. These home healthcare services are being developed in addition to hospital care, enabling patients to enjoy better quality of life and local authorities to reduce costs. Home healthcare represents about 50% of Air Liquide's revenue in Healthcare in 2016.
© Air Liquide 2019